Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Zabalafin Hydrogel
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Alphyn Doses First in CLEAR-AD1 Global Trial for Atopic Dermatitis
Details : AB-101a (zabalafin) hydrogel is a novel, first-in-class complex single-source botanical drug, which is being evaluated for the treatment of mild to moderate atopic dermatitis.
Product Name : AB-101a
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 12, 2025
Lead Product(s) : Zabalafin Hydrogel
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Zabalafin Hydrogel
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Alphyn Doses First Patient in Phase 2b CLEAR-AD1 Trial for Dermatitis
Details : AB-101a (zabalafin) hydrogel is a novel, first-in-class complex single-source botanical drug, which is being evaluated for the treatment of mild to moderate atopic dermatitis.
Product Name : AB-101a
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 08, 2025
Lead Product(s) : Zabalafin Hydrogel
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Zabalafin Hydrogel
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Alphyn Secures FDA Clearance of IND for Atopic Dermatitis
Details : AB-101a (zabalafin) hydrogel is a novel, first-in-class complex single-source botanical drug, which is being evaluated for the treatment of mild to moderate atopic dermatitis.
Product Name : AB-101a
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
February 19, 2025
Lead Product(s) : Zabalafin Hydrogel
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Zabalafin Hydrogel
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Alphyn Announces Positive Results from Phase 2a Trial in Atopic Dermatitis
Details : Alphyn lead product candidate AB-101a (zabalafin hydrogel) is being evaluated in the Phase II clinical trial studies with patients for the treatment of atopic dermatitis.
Product Name : AB-101a
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
July 03, 2024
Lead Product(s) : Zabalafin Hydrogel
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Zabalafin Hydrogel
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AB-101a is a novel, first-in-class complex single-source botanical drug with multiple bioactive compounds that provides multiple mechanisms of action, including anti-inflammatory, anti-pruritic, and antibacterial activity, indicating AB-101a could be eff...
Product Name : AB-101a
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
July 14, 2023
Lead Product(s) : Zabalafin Hydrogel
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Zabalafin Hydrogel
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AB-101a, is being developed as a topical treatment for AD, the most common form of eczema. AB-101a has demonstrated a strong safety profile and is in development to uniquely target AD's immune system and bacterial components.
Product Name : AB-101a
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
October 18, 2022
Lead Product(s) : Zabalafin Hydrogel
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable